Neimeth International Pharmaceuticals Plc is undertaking a major reorganisation of nearly N2 billion in reserves under a court-backed scheme, highlighting a growing shift in Nigeria’s pharmaceutical sector away from reliance on expensive short-term bank financing. The move reflects an industry-wide recalibration as companies confront rising borrowing costs and mounting operational pressures.
At a court-ordered meeting on March 31, shareholders approved the scheme of arrangement, clearing the way for Neimeth to reduce its share premium from N2.38 billion to N390.02 million and transfer the N1.99 billion balance into retained earnings. The restructuring, which still requires final approval from regulators and the court, aims to strengthen distributable reserves, absorb accumulated losses, and enhance financial flexibility—all without the need to raise fresh capital.
The board has been authorised to implement the plan and accept any necessary modifications demanded by the Securities and Exchange Commission (SEC) or the court. While technical in nature, the decision is emblematic of a broader trend among Nigerian pharmaceutical companies seeking to reshape balance sheets in response to a tightening financing environment.
Rising Borrowing Costs Force a Strategic Reset
For years, Nigerian pharmaceutical firms relied heavily on short-term bank loans to fund working capital, procurement, and expansion. Today, this model is under strain as borrowing costs soar.
The Central Bank of Nigeria maintains a benchmark Monetary Policy Rate of 26.5 percent, with commercial lending rates for manufacturers frequently exceeding 30 percent. In industries like pharmaceuticals—where production cycles are long and margins are thin—these rates fundamentally alter the economics of borrowing.
“Loans with interest rates as high as 33 percent make it nearly impossible for manufacturers to break even, especially in a capital-intensive industry like API production,” said Patrick Ajah, managing director of May & Baker Nigeria Plc.
As debt service obligations consume an increasing share of cash flow, companies find less liquidity available for production and expansion. What was once a flexible source of funding has become a constraint on growth, forcing firms to explore alternative financial strategies.
Import Dependence Amplifies Financial Pressure
High borrowing costs are only one part of the challenge. Nigeria’s pharmaceutical sector relies heavily on imported raw materials, with more than 70 percent of inputs sourced from abroad. This exposes companies to foreign exchange volatility and rising input costs, particularly for active pharmaceutical ingredients.
Global supply disruptions and geopolitical tensions have driven sharp price increases for key inputs like paracetamol, further intensifying working capital pressures. In combination with rising borrowing costs, these dynamics create a persistent liquidity squeeze, leaving companies with little room to maintain operations without restructuring.
Restructuring as a Strategic Necessity
Against this backdrop, Nigerian pharmaceutical companies are increasingly exploring ways to optimise financing. Options include extending loan tenors, renegotiating interest rates, converting short-term debt into longer-term obligations, or raising equity to reduce reliance on expensive borrowing. The goal is to restore financial stability and create operational flexibility.
Some companies have already acted decisively. Fidson Healthcare Plc raised approximately N21 billion through a rights issue in early 2026, strengthening its capital base and reducing reliance on short-term loans. “The successful formalisation of this N21 billion rights issue marks a critical milestone for Fidson,” said Biola Adebayo. “This capital will support our growth and strengthen our position in the market.”
Neimeth, which returned to profitability in 2025, is combining internal restructuring with debt adjustments and potential capital raising. Extending loan tenors has allowed the company greater operational breathing room, while the reserve reclassification strengthens its balance sheet and enhances flexibility in managing working capital.
A Sector-Wide Shift in Strategy
Neimeth’s actions mirror broader trends across the sector. Other listed players, including Mecure Industries Plc and May & Baker Nigeria Plc, face similar constraints, even if they have not publicly announced formal restructuring plans.
Market dynamics are accelerating the shift. The exit of multinational pharmaceutical companies such as GlaxoSmithKline and Sanofi has opened opportunities for local manufacturers, but capturing these gaps requires significant investment in manufacturing, regulatory compliance, and distribution networks. Such investments are ill-suited to short-term, high-interest loans.
Equity financing is increasingly attractive despite potential dilution, as it provides capital without immediate repayment obligations. Coupled with government incentives—like tax exemptions on hundreds of raw materials—firms are incentivised to invest in local production, reducing import dependence and long-term operational risk.
Neimeth’s recent restructuring highlights a more profound financial reset in Nigeria’s pharmaceutical industry. What may appear as a technical adjustment is, in reality, a strategic response to elevated borrowing costs, volatile input markets, and evolving sector dynamics. As firms move away from debt-driven growth, the landscape for financing pharmaceutical operations in Nigeria is being fundamentally reshaped.